Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal

Influenza Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled Trial of the Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01854632
• Other study ID #: LAIV-SEN-01
• Status: Completed
• Phase: Phase 3
• First received: May 13, 2013
• Last updated: June 1, 2015
• Start date: May 2013
• Est. completion date: December 2013

Study information

• Verified date: February 2014
• Source: PATH
• Contact: n/a
• Is FDA regulated: No
• Health authority: Senegal: National Ethics Commitee for Health Research, Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This study will provide the Senegal Ministry of Health with data on the clinical efficacy of the Live-Attenuated Influenza Vaccine (LAIV). This data will inform future policy considerations for influenza vaccine.

Description:

This study is a double-blind, individual-randomized, placebo-controlled, clinical efficacy trial among healthy children aged 24 through 71 months in the Niakhar area of Senegal. A total of 1,761 healthy children will be randomized in a 2:1 ratio of LAIV to placebo.

For evaluation of efficacy, passive and active surveillance will be conducted weekly throughout the study to identify outcomes among vaccinated subjects. Children meeting the protocol-defined clinical case definition will have a nasal swab and throat swab specimen collected for testing by rRT-PCR for evidence of influenza virus infection.

100 of the 1,761 participants were also included in a substudy designed to evaluate virologic evidence of LAIV replication. As such, nasal and throat swab specimens were collected on day 0 (prior to vaccination), as well as on post-vaccination days 2, and 4 from all subjects included in the substudy. These specimens will be tested for presence of wild-type and vaccine virus. Additionally, a more detailed assessment of vaccine reactogenicity will be made among these children by actively collecting solicited and unsolicited reactions at each study visit for the week post vaccination (days 2 and 4).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1761
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 24 Months to 71 Months

Eligibility

Inclusion Criteria:

• Healthy male or female child at least 24 months of age and no older than 71 months of age at the time of study vaccination.

• A child whose parent or guardian's primary residence, at the time of study vaccinations, is within the Niakhar DSS and who intends to be present in the area for the duration of the trial.

• A child whose parent or legal guardian is willing to provide written informed consent prior to the participant's study vaccination

Exclusion Criteria:

• Serious, active, medical condition, including: chronic disease of any body system,chronic infections such as tuberculosis, genetic disorders, such as Down's syndrome or other cytogenetic disorder, known or suspected disease of the immune system of any kind.

• History of documented hypersensitivity to eggs or other components of the vaccine (including gelatin, sorbitol, lactalbumin and chicken protein), or with life-threatening reactions to previous influenza vaccinations.

• History of Guillain-Barré syndrome.

• Receipt of immunosuppressive agents, including systemic corticosteroids, during the month before planned study vaccination.

• Receipt of aspirin therapy or aspirin-containing therapy within the two weeks before planned study vaccination.

• History of any severe allergic reaction with generalized urticarial, angioedema, or anaphylaxis.

• Receipt of an influenza vaccine within the past 12 months.

• Has any condition determined by investigator as likely to interfere with evaluation of the vaccine or be a significant potential health risk to the child or make it unlikely that the child would complete the study.

Temporary Contraindications:

• Acute illness accompanied by a body temperature of 37.5°C or above (axillary measurement) within 14 days of enrollment visit.

• Any acute respiratory infection within 14 days of enrollment visit.

• Any illness accompanied by active wheezing within 14 days of enrollment visit.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• SIIL Live Attenuated Influenza Vaccine
Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
• Matched placebo
Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.

Locations

Country	Name	City	State
Senegal	Institut de Recherche pour le Développement (IRD), Niakhar station	Niakhar

Sponsors (4)

Lead Sponsor	Collaborator
PATH	Centers for Disease Control and Prevention, Institut de Recherche pour le Developpement, Institut Pasteur de Dakar

Country where clinical trial is conducted

Senegal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Regardless of Vaccine Match)		Through 7 to 8 months post vaccination	No
Secondary	Safety Profile of LAIV: Immediate Reactions Occurring Within 30 Minutes of Administration of Study Vaccine.		Through 30 minutes post vaccination	Yes
Secondary	Safety Profile of LAIV: Solicited and Unsolicited Local and Systemic Reactions		Through 7 days post vaccination	Yes
Secondary	Safety Profile of LAIV: Serious Adverse Events		Through 1 month post vaccination	Yes
Secondary	Safety Profile of LAIV: Other Non-serious Adverse Events		Through 1 month post vaccination	Yes
Secondary	Safety Profile of LAIV: Protocol Defined Wheezing Illness		Through 7 to 8 months post vaccination	Yes
Secondary	Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection (Vaccine-matched Strains)		Through 7 to 8 months post vaccination	No
Secondary	Percentage of Participants With Symptomatic, Laboratory-confirmed Influenza Virus Infection by Influenza Type/Subtype (Influenza A/H1N1, Influenza A/H3N2, and Influenza B)		Through 7 to 8 months post vaccination	No
Secondary	Clinical Characteristics of Influenza in the Study Population		Through 7 to 8 months post vaccination	No
Secondary	Etiologies of Influenza-like Illness in the Study Population	Bacterial and viral etiologies of acute respiratory and febrile illness will be parameterized as the percentage of those with each particular laboratory-confirmed infection categorized by vaccine allocation.	Through 7 to 8 months post vaccination	No
Secondary	Evaluation of Vaccine-take as Shedding of Vaccine Virus Post-vaccination, Including Viral Load and Duration of Virus Detection	Vaccine take will be parameterized as the percentage of participants with detectable vaccine-virus in nasal or throat swab on each day pre- (day 0) and post vaccination (i.e., 2 and 4 days post vaccination), and the quantity of detected virus.	Through 4 days post vaccination	No